695 related articles for article (PubMed ID: 18258991)
1. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
[TBL] [Abstract][Full Text] [Related]
2. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
Buchholz TA; Lehman CD; Harris JR; Pockaj BA; Khouri N; Hylton NF; Miller MJ; Whelan T; Pierce LJ; Esserman LJ; Newman LA; Smith BL; Bear HD; Mamounas EP
J Clin Oncol; 2008 Feb; 26(5):791-7. PubMed ID: 18258988
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for locally advanced breast cancer.
Specht J; Gralow JR
Semin Radiat Oncol; 2009 Oct; 19(4):222-8. PubMed ID: 19732686
[TBL] [Abstract][Full Text] [Related]
4. [Role of radiation therapy on the use of primary ("neoadjuvant") systemic treatment of breast cancer].
Souchon R; Dunst J; Hartmann KA
Strahlenther Onkol; 2006 Apr; 182(4):202-9. PubMed ID: 16622621
[TBL] [Abstract][Full Text] [Related]
5. Research issues affecting preoperative systemic therapy for operable breast cancer.
Wolff AC; Berry D; Carey LA; Colleoni M; Dowsett M; Ellis M; Garber JE; Mankoff D; Paik S; Pusztai L; Smith ML; Zujewski J
J Clin Oncol; 2008 Feb; 26(5):806-13. PubMed ID: 18258990
[TBL] [Abstract][Full Text] [Related]
6. Primary systemic therapy of breast cancer.
Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
[TBL] [Abstract][Full Text] [Related]
7. Preoperative (neoadjuvant) systemic treatment of breast cancer.
Kaufmann M; von Minckwitz G; Rody A
Breast; 2005 Dec; 14(6):576-81. PubMed ID: 16199160
[TBL] [Abstract][Full Text] [Related]
8. The scientific value of preoperative studies and how they can be used.
Dixon JM
Breast Cancer Res Treat; 2004; 87 Suppl 1():S19-26. PubMed ID: 15597217
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ; Dixon JM
Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
[TBL] [Abstract][Full Text] [Related]
10. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.
Kaufmann M; von Minckwitz G; Smith R; Valero V; Gianni L; Eiermann W; Howell A; Costa SD; Beuzeboc P; Untch M; Blohmer JU; Sinn HP; Sittek R; Souchon R; Tulusan AH; Volm T; Senn HJ
J Clin Oncol; 2003 Jul; 21(13):2600-8. PubMed ID: 12829681
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant endocrine therapy for locally advanced breast cancer.
Ma CX; Ellis MJ
Semin Oncol; 2006 Dec; 33(6):650-6. PubMed ID: 17145344
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
13. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Mauri D; Pavlidis N; Ioannidis JP
J Natl Cancer Inst; 2005 Feb; 97(3):188-94. PubMed ID: 15687361
[TBL] [Abstract][Full Text] [Related]
15. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
16. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
[TBL] [Abstract][Full Text] [Related]
17. [Breast cancer].
Kobayashi T; Yamazaki H; Nakamura T; Ogihara A; Fujii T; Hirano A; Uno S; Yoshida K; Nagata T; Uchida K; Kubo H; Tozaki M; Kanehira C; Miyazawa Y; Suzuki M; Kuraishi Y
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1814-25. PubMed ID: 11729473
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
19. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
Colleoni M; Viale G; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S137-40. PubMed ID: 19914533
[TBL] [Abstract][Full Text] [Related]
20. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
